Atai Life Sciences N.V. (ATAI): רווח נקי למניה ב-12 החודשים האחרונים

Atai Life Sciences N.V. (ATAI) is developing an advanced R&D pipeline of psychedelic therapies for depression. The rolling trailing twelve-month earnings per share on the GURU.Markets chart reflects the impact of decentralized asset management and the leadership's scientific expertise, although geopolitical tensions and logistical disruptions are hindering global trials. The current value of -2.21 determines this specific profit parameter level.
פילוחים אנליטיים ודוחות נתונים של חברת atai Life Sciences Corp (ATAI)

Annual net income per share determines real business efficiency by dividing total income by the number of securities to identify the issuer's fundamental strength. By analyzing the current annual net income per share metric on GURU.Markets, an investor assesses the monetization potential of Atai Life Sciences N.V. (ATAI) innovations in the field of psychedelic therapy, where future government contracts are expected to transform investment expenditures into sustainable profit growth.